S-HERTOGENBOSCH, Netherlands–(BUSINESS WIRE)–Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, today announces that the EMA Committee for Orphan Medicinal Products (COMP) has recommended the granting of orphan medicinal product designation for MesoPher in pancreatic cancer.
MesoPher is comprised of autologous dendritic cells loaded with PheraLys, a lysate of tumour cell lines. PheraLys contains a broad repertoire of tumour-associated antigens, many of which are present in pancreatic cancer and other cancers.
In December 20221, Amphera reported topline results from the phase II REACTIVE trial in patients with resected pancreatic cancer. MesoPher demonstrated a statistically significant 2-year Recurrence Free Survival of 60% and an excellent safety profile.
1) https://www.amphera.nl/amphera-announces-clinical-updates-of-mesopher-cell-therapy/
Notes to Editors
About EMA Orphan Designation
Source: https://www.ema.europa.eu/en/documents/leaflet/leaflet-orphan-medicines-eu_en.pdf
“The EU offers incentives to encourage companies to research and develop medicines for rare diseases that otherwise would not be developed. To access these incentives, companies can apply for orphan designation for their medicine, provided certain criteria are met.
Criteria for orphan designation:
During an orphan medicine’s research and development, the company can benefit from incentives such as scientific advice on study protocols, various fee reductions and access to EU grants. Orphan-designated medicines that eventually make it to the market, and for which it can be demonstrated that they maintain the criteria for the designation, are granted 10 years of market exclusivity.
Orphan designation is not an authorization: Not all orphan-designated medicines reach the marketing authorisation application stage. Those that do, are evaluated by EMA’s Committee for Medicinal Products for Human Use (CHMP) using the same strict safety and efficacy standards that apply to all medicines evaluated by EMA.”
About Amphera
For more information: www.amphera.nl
Contacts
Amphera BV
Rob Meijer (CEO) rob.meijer@amphera.nl
Special Working Group Committed to Strengthening Chinese Investment in Preah Sihanouk Province HONG KONG SAR…
HONG KONG SAR - Media OutReach Newswire - 1 November 2024 - On the evening…
HONG KONG SAR - Media OutReach Newswire - 1 November 2024 - Paul Chan, Financial…
Enticing promotions to thank customers for their support HONG KONG SAR - Media OutReach Newswire…
HO CHI MINH CITY, VIETNAM – Media OutReach Newswire – 1 November 2024 - Ho…
HONG KONG SAR – Media OutReach Newswire - 1 November 2024 – Lionrock Property is…